Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the activity of factor XI, a clotting protein that helps your blood form stable clots. The assay evaluates how well factor XI in your plasma functions within the intrinsic pathway of coagulation. Results are reported in activity units relative to normal pooled plasma.
The method uses a standardized dilution of your plasma to ensure the measurement falls within the analytical range of the test. It is different from antigen tests that measure how much of the protein is present; this assay focuses on how well the protein works.
Clinicians order factor XI activity testing when there is unexplained easy bruising, nosebleeds, heavy menstrual bleeding, or prolonged bleeding after procedures, as well as for preoperative assessment in people with a personal or family history suggestive of a bleeding tendency. It helps identify congenital factor XI deficiency and can detect acquired reductions due to medical conditions.
Abnormal results may be seen with liver disease, the development of an inhibitor against factor XI, or consumption of clotting factors in complex illnesses. In some people, higher factor XI activity has been associated with a tendency to form clots. Understanding your level can guide planning for surgery, dental work, or childbirth and inform the safe use of blood products or other therapies.
A lower-than-expected factor XI activity suggests a deficiency, which may be inherited or acquired. Not everyone with a low result will have significant bleeding, and the severity of symptoms does not always match the activity level. Your clinician will interpret your result alongside your bleeding history, medications, and other coagulation tests.
A result within the expected range generally indicates adequate factor XI function, but it does not completely rule out a mild bleeding risk in all situations. If your value is higher than expected or you have risk factors for clotting, your clinician may consider the overall clinical context to decide whether any action is needed.
If results are unexpected, repeat testing or additional studies may be recommended, such as evaluating for inhibitors, checking other clotting factors, or reviewing potential medication effects. Always discuss stopping or starting any medication, including anticoagulants, only with your care team.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
This assay requires a full citrate tube and timely processing. Underfilling, clots in the tube, prolonged tourniquet time, or delays and extreme temperatures during transport can falsely lower or raise the measured activity.
Heparin, direct thrombin inhibitors, and direct oral anticoagulants can interfere with clot-based assays and may lower the apparent activity. Tell your clinician about all blood thinners; do not stop them unless advised.
Because factor XI is produced in the liver, liver dysfunction, disseminated intravascular coagulation, or severe illness can reduce activity. Improvement often parallels recovery of the underlying condition.
An acquired inhibitor directed against factor XI or the presence of lupus anticoagulant can alter clot-based results. Mixing studies and specific inhibitor assays may be needed if results are incongruent with your history.
Newborns can have lower physiologic activity that rises with age. Pregnancy and estrogen therapy can change multiple clotting factors and may influence interpretation, so laboratories and clinicians consider clinical context.
Inherited factor XI deficiency is more common in certain populations and families. If you have a personal or family history of bleeding, genetic or family studies may be discussed alongside your activity result.
References